AriBioLab Co.,Ltd. (KOSDAQ:261780)
South Korea · Delayed Price · Currency is KRW 2,595.00
+130.00 (5.27%)
At close: Sep 3, 2026
AriBioLab Revenue
AriBioLab had revenue of 173.16M KRW in the twelve months ending June 30, 2026, up 9.17% year-over-year. In the year 2025, AriBioLab had annual revenue of 158.62M, down -57.21%.
Revenue (ttm)
173.16M
Revenue Growth
+9.17%
P/S Ratio
426.29
Revenue / Employee
n/a
Employees
n/a
Market Cap
73.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 158.62M | -212.04M | -57.21% |
| Dec 31, 2024 | 370.66M | 76.53M | 26.02% |
| Dec 31, 2023 | 294.12M | 114.64M | 63.87% |
| Dec 31, 2022 | 179.48M | -320.52M | -64.10% |
| Dec 31, 2021 | 500.00M | 422.20M | 542.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 131.54B |
| Psomagen | 60.70B |
| J2KBIO | 43.90B |
| Naturalendo Tech | 22.79B |
| BIO-FD&C | 19.53B |
| PanGen Biotech | 14.18B |
| ADBiotech | 12.51B |
| EyeGene | 4.02B |